Company Overview and News

 
First Connecticut Bancorp's (FBNK) CEO John Patrick on Q1 2018 Results - Earnings Call Transcript

4h seekingalpha
First Connecticut Bancorp, Inc. (NASDAQ:FBNK) Q1 2018 Earnings Conference Call April 19, 2018 10:30 AM ET
Upvote Downvote

 
Will Weak Margins in Aviation Segment Hurt GE's Q1 Earnings?

2018-04-18 zacks
General Electric Company (GE - Free Report) is scheduled to report first-quarter 2018 results on Apr 20, before the opening bell. The company’s Aviation segment is likely to report lower profit in the quarter, thanks to challenging market conditions.
Upvote Downvote

 
Will Healthcare Revenue Growth Sustain GE's Q1 Earnings?

2018-04-18 zacks
General Electric Company (GE - Free Report) is scheduled to report first-quarter 2018 results on Apr 20, before the opening bell. The company’s Healthcare segment is likely to report higher revenues and strong margins, owing to improved market dynamics and growth in medical diagnostics market.
Upvote Downvote

 
Clouds Start Gathering around General Electric’s Dividend

2018-04-17 marketrealist
A series of financial miscalculations have marred General Electric (GE) stock recently. Among all major industrial (IYJ) companies, GE still evokes the highest levels of investor anxiety. In November 2017, the industrial behemoth took multiple measures to instill financial discipline.
Upvote Downvote

 
Can General Electric Beat Analysts’ 1Q18 Revenue Estimate?

2018-04-17 marketrealist
A spate of financial surprises by General Electric (GE) has taken the investor community by surprise. Due to the implementation of new revenue recognition rules, the value of GE’s contract assets has been written off. However, the company maintains that it hasn’t altered the value of its long-term contracts—or, in turn, its cash flows and earnings estimates for 2018.
Upvote Downvote

 
EU mergers and takeovers (April 17)

2018-04-17 reuters
BRUSSELS, April 17 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
Upvote Downvote

 
EU mergers and takeovers (April 16)

2018-04-16 reuters
BRUSSELS, April 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
Upvote Downvote

 
2019 Dividend Aristocrat Newcomers

2018-04-16 seekingalpha
In this article I outline five companies who are on the brink of making it onto the coveted Dividend Aristocrats list.
Upvote Downvote

 
Honeywell’s Revenue: Could 1Q18 Be Its Best-Ever 1st Quarter?

2018-04-16 marketrealist
Honeywell (HON) is expected to report revenue of $10.0 billion in 1Q18, representing a 5.7% increase from 1Q17’s $9.5 billion. If HON manages to meet expectations, it will achieve its highest first-quarter revenue ever, and mark a first-quarter CAGR (compound annual growth rate) of 1.5% since 2013.
Upvote Downvote

 
Honeywell’s Stock Performance since Its 4Q17 Earnings Release

2018-04-16 marketrealist
Honeywell (HON) is set to announce its 1Q18 earnings on April 20, 2018, before the market opens. It plans to hold a conference call that day, at 7:30 AM EST (Eastern Standard Time). In this series, we’ll look at Honeywell’s stock performance since its 4Q17 earnings, and analysts’ revenue and EPS (earnings per share) estimates and recommendations. We’ll also compare HON’s latest valuation and short interest with peers’.
Upvote Downvote

2
China's Secret Weapon

2018-04-13 seekingalpha
Measures China could take to even its score with the U.S. and what U.S. companies that could get hurt the most if relations sour to the extreme.
Upvote Downvote

 
Pulse Check On Industrials: Q1 Valuations Rich

2018-04-13 seekingalpha
While not a large cap investor, keeping an eye on growth, trends, and management commentary from the biggest firms in the industry help guide small cap decision making.
Upvote Downvote

 
Microsoft Corporation Goes All-In on the Internet of Things

2018-04-12 investorplace
When it comes to understanding the secular trends in technology, Microsoft Corporation (NASDAQ:MSFT) CEO Satya Nadella has been spot on. When he took the helm of the company in 2014, he took swift action to focus on the cloud. And yes, the results have been standout. Note that during the past three years, the compound annual growth rate for Microsoft stock has been a sizzling 32.63%.
Upvote Downvote

 
General Electric to Supply Jenbacher Gas Engines to Russia

2018-04-12 zacks
General Electric Company (GE - Free Report) inked a supply agreement with GreenTech Energy Company (a GE-authorized channel partners) to deliver 21 Jenbacher gas engines to be delivered by the end of 2018. This is one of GE’s biggest contracts for Jenbacher engines in the Russian market.
Upvote Downvote

 
United Technologies Expands GTF Engine Repair Supplier Base

2018-04-12 zacks
United Technologies Corporation’s (UTX - Free Report) operating segment, Pratt & Whitney, recently announced its decision to include five repair suppliers in its global network of providers that maintain the Geared Turbofan (GTF) engine. This, in turn, will support the PW1100G-JM engine.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 913017109